In our series no significant association was found between the presence and relative quantification of KRAS mutation in plasma and tumour burden, in terms of the number of metastatic sites or the presence of bone and/or liver metastases (Supplementary Table 7). The gene discussed is KRAS; the disease is neoplasm.